MONROVIA, CA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. (OTC Markets "ECPO", “Immunotech” or the “Company”) announced today that negotiations have begun with one of the World’s premier providers of state of the art Clinical Trial Supply services, for a Quality Person (“QP”) for the receipt and distribution of the Company’s validation order. Securing a delivery and disbursement partner is one of the last steps in receiving the Permit process.
In addition, the newly appointed Advisory Board Member, Dr. Hui, reported that his representation of the Company at the 2018 Asia -Pacific Precision Medicine Forum was successfully received by the many of the Pharmaceutical and Medical professionals attending the Symposium.
Dr. Hui is an expert on metabolic diseases, oncology and wellness. He also serves as an active consultant for government and industry in medical and biotechnological areas. He is the author of over 150 scientific papers and dozen patents on metabolic and cancer studies. He is an associate editor of “Pancreas” and “Frontier in Gastrointestinal Science”, and serves as editor board on 8 professional journals.
“The Company continues to make strides in its efforts to bring its Immunotherapy to Market in Eastern Europe and is pleased with the first steps it has taken in exploring the receptiveness to its technology in Asia,” stated Harry Zhabilov, CEO.
Immunotech, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind
Immunotech’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Immunotech believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests.
Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech or any other person that the objectives and plans of Immunotech will be achieved should not regard the forward-looking statements as a representation.
CONTACT: IR Contact: Immunotech Laboratories, Inc. 120 W Pomona Ave Monrovia, CA 91016 Phone: (626) 538-4779 Fax: (626) 538-4779